(R)-N-Desacryloyl N-Propionyl Ibrutinib

(R)-N-Desacryloyl N-Propionyl Ibrutinib, also known as R-NDPI, is a novel derivative of Ibrutinib, a potent inhibitor of Bruton’s tyrosine kinase (BTK). BTK is an enzyme that plays a crucial role in the activation of B-cells and is a key target in the treatment of B-cell malignancies, such as chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström macroglobulinemia. R-NDPI has shown promising results in preclinical studies as a more potent and selective inhibitor of BTK than Ibrutinib. It has also demonstrated improved pharmacokinetic properties, including increased bioavailability and longer half-life. These properties suggest that R-NDPI may have greater clinical efficacy and fewer side effects than Ibrutinib. Chemically, R-NDPI is a small molecule with a molecular weight of 466.58 g/mol. Its chemical structure consists of a propionyl group and a desacryloyl group attached to the nitrogen atom of the imidazo[1,2-b]pyridazine core of Ibrutinib. In summary, R-NDPI is a promising new derivative of Ibrutinib that has the potential to provide improved clinical outcomes for patients with B-cell malignancies. Its chemical properties and mechanism of action make it an exciting prospect for further development and study in the field of cancer therapy.